Measuring Lipoprotein(a) for Cardiovascular Disease Prevention - In Whom and When?
Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the...
Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025.
Share
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
Source : https://link.springer.com/article/10.1007/s11883-023-01166-3
An evidence for lipid lowering therapy in heart failure is briefly summarized in this review. Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and...
PCSK9 inhibitors, new lipid-lowering drugs, are very effective in LDL-C lowering and prevention of ASCVD. The role of PCSK9 inhibitors in HF treatment is investigated.
Share
Dyslipidaemia as a Target for Atherosclerotic Cardiovascular Disease Prevention in Children With Type 1 Diabetes: Lessons Learned From Familial Hypercholesterolaemia
Source : https://pubmed.ncbi.nlm.nih.gov/38032368/
In the last few decades, atherosclerotic cardiovascular disease (ASCVD) risk has decreased dramatically among individuals affected by familial hypercholesterolaemia (FH) as a result of the early initiation of statin treatment...
Although the pathogenesis of ASCVD in type 1 diabetes is multifactorial, and long-term trials of lipid-lowering therapy in children, including imaging, are lacking, there is a strong rationale for early and aggressive ASCVD risk management in children with type 1 diabetes, with an increasing role for statins.
Share
PCSK9 Inhibitors: Current Status and Emerging Frontiers in Lipid Control
Source : https://pubmed.ncbi.nlm.nih.gov/37996219/
Among PCSK9 inhibitors, monoclonal antibodies represent a cornerstone. Many trials have showed their efficacy in reducing LDL-C and the risk for major adverse clinical events, revealing long-lasting effects, with special...
Monoclonal antibodies, gene silencing, binding peptides, and active immunization are among the innovative pharmacologic strategies being explored for PCSK9 inhibition.
Share
Health Economics of Detection and Treatment of Children With Familial Hypercholesterolemia: to Screen or Not to Screen Is No Longer the Question
Here, we review the recent literature on health economic outcomes for the detection and management of FH in children. Recent findings A targeted literature review identified eight studies evaluating detection...
Detection and management of HeFH in pediatric populations was cost effective, regardless of the age of the children.
Share